Nextrials, Inc. launched an Apple® iPad™ slate computer application for its clinical trial data management platform, Prism . The application supports mobile access to patient data in clinical trial and health care settings, helping physicians and researchers deliver superior care. It is also usable on an Apple iPhone™, and will be available as a free download later this year through the Apple® iTunes® Store.
Attendees at the 46th Annual Meeting of the Drug Information Association (DIA), being held June 13-17 at the Walter E. Washington Convention Center in Washington, DC, can get a first look at how Prism supports anytime/anywhere data access. In addition, DIA participants will see:
-Prism’s new design tools to foster faster study starts, the result of a recently announced strategic partnership with Formedix
-Nextrials’ participation in a live Healthcare Link demonstration showcasing shared data between clinical trial researchers and healthcare organizations, sponsored by the Clinical Data Interchange Standards Consortium
Nextrials’ Prism melds clinical trial management functionality with EDC in a single package. By receiving a constant flow of data, Prism enables sponsors and sites to fully utilize real-time integration of disparate information and data sources, such as a hospital’s EHR or patient records, to better provide a continuum of care for patients enrolled in clinical trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.